Clinical Trial Update: Sintilimab (IBI308) Combined With Bevacizumab + XELOX Regimen in Metastatic Colorectal Cancer [Phase 2]

View source ↗

Summary

Phase 2 trial evaluating Sintilimab combined with Bevacizumab and XELOX in metastatic colorectal cancer with RAS mutation (MSI-stable).

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Colorectal Cancer

Drugs mentioned

• Bevacizumab (bevacizumab)
• Sintilimab (sintilimab)
• XELOX regimen

Snippet

Sponsor: Second Affiliated Hospital, School of Medicine, Zhejiang University | Conditions: Metastatic Colorectal Cancer, RAS Mutation | Phase 2 | Status: UNKNOWN